Computer tomographic and laboratory predictors of clinical outcomes of acute ischemic stroke patients after the systemic thrombolytic therapy

Shamalov N.A.; Skvortsova V.I.; Ramazanov G.R.; Anisimov K.V.; Karpova O.V.; Kochetov A.G.; Luk'ianov A.L.; Gubskiĭ L.V.

doi:https://doi.org/

Shamalov N.A.

Research Institute of cerebrovascular pathology and stroke of the Pirogov Russian national research medical University, Moscow, Russia

SPIN RSCI: 2865-9817
Scopus AuthorID: 6507183111
ORCID: 0000-0001-6250-0762

Skvortsova V.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
NII tserebrovaskuliarnoĭ patologii i insul'ta, Moskva

Ramazanov G.R.

Sklifosovsky research Institute for ambulance, Moscow, Russia

Anisimov K.V.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Karpova O.V.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Kochetov A.G.

Tsentr kardiokhirurgii i tsentr urologii 3-go Tsentral'nogo voennogo klinicheskogo gospitalia im. A.A. Vishnevskogo MO RF, Moskovskaia oblast', Krasnogorsk

Luk'ianov A.L.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Gubskiĭ L.V.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Computer tomographic and laboratory predictors of clinical outcomes of acute ischemic stroke patients after the systemic thrombolytic therapy

Authors:

Shamalov N.A., Skvortsova V.I., Ramazanov G.R., Anisimov K.V., Karpova O.V., Kochetov A.G., Luk'ianov A.L., Gubskiĭ L.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(4‑2): 21‑28

Read: 1335 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shamalov NA, Skvortsova VI, Ramazanov GR, et al. . Computer tomographic and laboratory predictors of clinical outcomes of acute ischemic stroke patients after the systemic thrombolytic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(4‑2):21‑28. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Clinical and epidemiological indicators of stroke during the COVID-19 pandemic and in the post-COVID period in the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):5-11

Clinical and genetic associations in patients with non-cardioembolic ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):12-19

Biomarkers of atherothrombotic and cardioembolic subtypes of acute ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):20-26

Clinical and tomographic comparisons in patients with aphasia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):27-33

Neuroimaging predictors of hemorrhagic transformation of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):34-38

Neurocytoprotection advances in reperfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12-2):75-88

Stroke: current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):7-18

The effectiveness of drug therapy in the rehabilitation of patients with post-stroke aphasia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):132-139

Oxidative stress and antioxidant protection in disorders of cerebral circulation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):114-119

Sequential use of botulinum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):80-85

Abstract:

Today the systemic thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is the most effective treatment of ischemic stroke. We included 116 patients with stroke, 82 received rt-PA, 34 were enrolled to the control group. Median NIHSS score was 16,2±5,4 in the main group and 16,2±5,4 in the control group. The trial revealed the prognostic significance of some early CT sings of ischemic brain damage for the hemorrhagic transformation and functional outcomes to the 90th day. It was shown that hyperfibrinogenemia (over 450 mg/dl) might be a risk factor of the hemorrhagic transformation. The excess of segmental leukocytes over 78% might be a predictor of the lethal outcome. The initial activity of tissue plasminogen inhibitor (first type) over 11,65 IU/L might be a risk factor of the vascular reocclusion after successful thrombolysis. The analysis of characteristic curves of leukocyte elastase revealed the informativeness of its initial values in the prognosis of reocclusion and hemorrhagic transformation.

Keywords:

ischemic stroke

thrombolysis

Authors:

Shamalov N.A.

Research Institute of cerebrovascular pathology and stroke of the Pirogov Russian national research medical University, Moscow, Russia

SPIN RSCI: 2865-9817
Scopus AuthorID: 6507183111
ORCID: 0000-0001-6250-0762

Skvortsova V.I.

Rossiĭskiĭ gosudarstvennyĭ meditsinskiĭ universitet;
NII tserebrovaskuliarnoĭ patologii i insul'ta, Moskva

Ramazanov G.R.

Sklifosovsky research Institute for ambulance, Moscow, Russia

Anisimov K.V.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Karpova O.V.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Kochetov A.G.

Tsentr kardiokhirurgii i tsentr urologii 3-go Tsentral'nogo voennogo klinicheskogo gospitalia im. A.A. Vishnevskogo MO RF, Moskovskaia oblast', Krasnogorsk

Luk'ianov A.L.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Gubskiĭ L.V.

Nauchno-issledovatel'skiĭ institut tserebrovaskuliarnoĭ patologii i insul'ta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Close metadata

References:

http://www.eso-stroke.org
Gregory J. del Zoppo, Jeffrey L. Saver, Edward C. Jauch, Harold P. Adams, Jr. and on behalf of the American Heart Association Stroke Council. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator. A Science Advisory From the American Heart Association/American Stroke Association. Stroke 2009; 40.
Tissue Plasminogen Activator For Acute Ishemic Stroke. New Engl J Med 1995; 333: 24.
Hacke W., Kaste M., Fieschi C. et al. For the ECASS Study Group. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 13.
Hacke W., Kaste M., Fieschi C. et al. For the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 9136: 1245-1251.
Wayne M. Clark, Stanley Wissman, Gregory W. Albers et al. For the ATLANTIS Study Investigators. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999; 282: 2019-2026.
The ATLANTIS, ECASS, AND NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
Werner H., Kaste M., Bluhmki E. et al. For the ECASS Investigators. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med 2008; 359: 13: 1729.
Ingall T.J., O’Fallon W.M., Asplund K. et al. Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial. Stroke 2004; 35: 2418-2424.
Del Zoppo G.J., Saver J.L., Jauch E.C., Adams H.P. On behalf of the American Heart Association Stroke Council. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator. A Science Advisory From the American Heart Association/American Stroke Association. Stroke 2009; 40.
Brott T.G., Adams H.P. Jr, Olinger C.P. et al. Measurement of acute cerebral infarction: a clinical examination scale. Stroke 1998; 20: 964-970.
Bonita R., Beaglehole R. Modification of Rankin Scale: Recovery of motor function after Stroke. Stroke 1988; 12: 1497-1500.
Mahouney F.I., Barthel D. Functional evaluation: the Barthel Index. Maryland State Medical Journal 1965; 14: 56-61.
Barber P.A., Demchuk A.M., Zhang J., Buchan A.M. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355: 1670-1674.
Fiorelly M., Bastianello S., von Kummer R. et al. For the ECASS I Study Group. Hemorrhagic transformation within 36 hours of a cerebral infarct. Relationship with early clinical deterioration and 3-month outcome in the ECASS I cohort. Stroke 1999; 30: 2280-2284.
Adams H., Bendixen B., Kappelle J. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993; 24: 1: 35-40.
Barber A. Philip, Demchuk M. Andrew, Hudon E. Mark et al. Hyperdense Sylvian Fissure MCA «Dot» Sign A CT Marker of Acute Ischemia. Stroke 2001; 32: 84-88.
Leys D., Pruvo J.P., Godefroy O. et al. Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992; 23: 317-324.
Demchuk A.M., Hill M.D., Barber P. et al. Levine for the NINDS rtPA Stroke Study Group, NIH. Importance of Early Ischemic Computed Tomography Changes Using ASPECTS in NINDS rtPA Stroke Study. Stroke 2005; 36: 2110-2115.
Dzialowski I., Hill D., Shelagh B. Coutts et al. Extent of Early Ischemic Changes on Computed Tomography (CT) Before Thrombolysis: Prognostic Value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006; 37: 973-978.
Kalafut M.A., Schriger D.L., Saver J.L., Starkman S. Detection of Early CT Signs of >¹/₃ Middle Cerebral Artery Infarctions: Interrater Reliability and Sensitivity of CT Interpretation by Physicians Involved in Acute Stroke Care. Stroke 2000; 31: 1667-1671.
Woodward M., Lowe G.D., Campbell D.J. et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36: 2143-2147.
Turaj W., Slowik A., Dziedzic T. et al. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 2006; 246: 13-19.
Del Zoppo G.J., Levy D.E., Wasiewski W.W. et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009; 40: 1687-1691.
Martí-Fàbregas J., Borrell M., Cocho D. et al. Change in Hemostatic Markers After Recombinant Tissue-Type Plasminogen Activator Is Not Associated With the Chance of Recanalization. Stroke 2008; 39: 234-236.
Cocho D., Borrell M., Martí-Fàbregas J. et al. Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage inPatients Treated With Tissue Plasminogen Activator. Stroke 2006; 37: 996-999.
Trouillas P., Derex L., Philippeau F. et al. Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis: A Study of 157 Cases. Stroke 2004; 35: 1323-1328.
Tanne D., Macko R.F., Yan Lin et al. Levine and for the NINDS rtPA Stroke Study Group. Hemostatic Activation and Outcome After Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke. Stroke 2006; 37: 1798-1804.
González-Conejero R., Fernández-Cadenas I., Iniesta J.A. et al. For the Proyecto Ictus Research Group. Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients. Stroke 2006; 37: 2288-2293.